Oncology Venture seeks to in-license drugs that almost made it to the marketing approval but didn’t beat the gold standard. By developing a multiple biomarker DRP™ and use it for screening of patients the population enrichment is assumed to increase the response rate to such an extent that a small focused phase 2 trial is believe to create clinical Proof of Concept for the drug.